The power of TAGLN promoter hypermethylation as an epigenetic diagnosis biomarker seems promising and should be validated for detection of tumor DNA from serum, plasma, or nipple and ductal fluids in a large, prospective screening study. This evidence concerns the gene TAGLN and neoplasm.